Clinical Trial

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-17; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT07039669
Lead Sponsor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions Pulmonary Disease, Chronic Obstructive (COPD)
Enrollment 594 participants
Start Date 2025-07-16
Primary Completion 2028-09 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-18